Changes in erythropoiesis-stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis : A prospective multicenter study in Japan
© 2023 International Society for Apheresis and Japanese Society for Apheresis..
INTRODUCTION: Inadequate dialysis and fluid overload are corrected after starting combined therapy with peritoneal dialysis (PD) and hemodialysis (HD). However, the effects on anemia management has not been elucidated.
METHODS: We conducted a prospective, multicenter, observational cohort study of 40 PD patients (age, 60 ± 10 years; male, 88%; median PD duration, 28 months) starting combined therapy and investigated changes in several clinical parameters, including erythropoiesis-stimulating agent (ESA) resistance index (ERI).
RESULTS: ERI decreased significantly during 6 months after switching to combined therapy (from 11.8 [IQR 8.0-20.4] units/week/kg/(g/dL) to 7.8 [IQR 3.9-18.6] units/week/kg/(g/dL), p = 0.047). Body weight, urinary volume, serum creatinine and the dialysate-to-plasma creatinine ratio (D/P Cr) decreased, whereas hemoglobin and serum albumin increased. In subgroup analysis, the changes in ERI were not affected by cause for starting combined therapy, PD holiday and D/P Cr.
CONCLUSION: Although detailed mechanism was unclear, ESA responsiveness improved after switching from PD alone to combined therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy - 27(2023), 4 vom: 10. Aug., Seite 735-741 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maruyama, Yukio [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.07.2023 Date Revised 04.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1744-9987.13981 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35402759X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35402759X | ||
| 003 | DE-627 | ||
| 005 | 20231226061334.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1744-9987.13981 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1180.xml |
| 035 | |a (DE-627)NLM35402759X | ||
| 035 | |a (NLM)36897071 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maruyama, Yukio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Changes in erythropoiesis-stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis |b A prospective multicenter study in Japan |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.07.2023 | ||
| 500 | |a Date Revised 04.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 International Society for Apheresis and Japanese Society for Apheresis. | ||
| 520 | |a INTRODUCTION: Inadequate dialysis and fluid overload are corrected after starting combined therapy with peritoneal dialysis (PD) and hemodialysis (HD). However, the effects on anemia management has not been elucidated | ||
| 520 | |a METHODS: We conducted a prospective, multicenter, observational cohort study of 40 PD patients (age, 60 ± 10 years; male, 88%; median PD duration, 28 months) starting combined therapy and investigated changes in several clinical parameters, including erythropoiesis-stimulating agent (ESA) resistance index (ERI) | ||
| 520 | |a RESULTS: ERI decreased significantly during 6 months after switching to combined therapy (from 11.8 [IQR 8.0-20.4] units/week/kg/(g/dL) to 7.8 [IQR 3.9-18.6] units/week/kg/(g/dL), p = 0.047). Body weight, urinary volume, serum creatinine and the dialysate-to-plasma creatinine ratio (D/P Cr) decreased, whereas hemoglobin and serum albumin increased. In subgroup analysis, the changes in ERI were not affected by cause for starting combined therapy, PD holiday and D/P Cr | ||
| 520 | |a CONCLUSION: Although detailed mechanism was unclear, ESA responsiveness improved after switching from PD alone to combined therapy | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ESA resistance index (ERI) | |
| 650 | 4 | |a dialysate-to-plasma ratio of creatinine (D/P Cr) | |
| 650 | 4 | |a erythropoiesis-stimulating agent (ESA) | |
| 650 | 4 | |a residual kidney function (RKF) | |
| 650 | 4 | |a β2 microglobulin | |
| 650 | 7 | |a Hematinics |2 NLM | |
| 650 | 7 | |a Hemoglobins |2 NLM | |
| 700 | 1 | |a Yokoyama, Keitaro |e verfasserin |4 aut | |
| 700 | 1 | |a Higuchi, Chieko |e verfasserin |4 aut | |
| 700 | 1 | |a Sanaka, Tsutomu |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Yoshihide |e verfasserin |4 aut | |
| 700 | 1 | |a Sakai, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Kanno, Yoshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Ryuzaki, Munekazu |e verfasserin |4 aut | |
| 700 | 1 | |a Sakurada, Tsutomu |e verfasserin |4 aut | |
| 700 | 1 | |a Hosoya, Tatsuo |e verfasserin |4 aut | |
| 700 | 1 | |a Nakayama, Masaaki |e verfasserin |4 aut | |
| 700 | 0 | |a EARTH (Evaluation of the Adequacy of Renal replacement THerapy) study group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy |d 2003 |g 27(2023), 4 vom: 10. Aug., Seite 735-741 |w (DE-627)NLM126443165 |x 1744-9987 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:4 |g day:10 |g month:08 |g pages:735-741 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1744-9987.13981 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e 4 |b 10 |c 08 |h 735-741 | ||